Abstract
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor characterized by initial response to chemotherapy and radiotherapy followed by relapse and rapid progression. Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand that is highly expressed on the surface of most SCLC tumors; DLL3 expression is minimal and mainly cytoplasmic in normal tissues. AMG 757 is an investigational HLE BiTE immune therapy designed to redirect cytotoxic T cells to SCLC cells by binding to DLL3 on tumor cells and CD3 on T cells, resulting in T-cell activation and expansion and T cell–dependent killing of tumor cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
